doi: 10.1161/01.RES.0000225982.01988.93
© 2006 American Heart Association, Inc.
Review |
Endothelial and Antithrombotic Actions of HDL
From the Division of Pulmonary and Vascular Biology (C.M., P.W.S.), Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas; and Department of Molecular and Experimental Medicine (H.D., J.H.G.), The Scripps Research Institute, La Jolla, Calif.
Correspondence to Philip W. Shaul, Division of Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9063. E-mail philip.shaul{at}utsouthwestern.edu
This Review is part of a thematic series on New Pathways in HDL Metabolism, which includes the following articles:
Antiinflammatory Properties of HDL
Genetics of Variation in HDL Cholesterol in Humans and Mice New Insights Into the Regulation of HDL
Metabolism and Reverse Cholesterol Transport
Endothelial and Antithrombotic Actions of HDL
Daniel Rader Guest Editor
It is well recognized that high-density lipoprotein (HDL)-cholesterol is antiatherogenic and serves a role in mediating cholesterol efflux from cells. However, HDL has multiple additional endothelial and antithrombotic actions that may also afford cardiovascular protection. HDL promotes the production of the atheroprotective signaling molecule nitric oxide (NO) by upregulating endothelial NO synthase (eNOS) expression, by maintaining the lipid environment in caveolae where eNOS is colocalized with partner signaling molecules, and by stimulating eNOS as a result of kinase cascade activation by the high-affinity HDL receptor scavenger receptor class B type I (SR-BI). HDL also protects endothelial cells from apoptosis and promotes their growth and their migration via SR-BI–initiated signaling. As importantly, there is evidence of a variety of mechanisms by which HDL is antithrombotic and thereby protective against arterial and venous thrombosis, including through the activation of prostacyclin synthesis. The antithrombotic properties may also be related to the abilities of HDL to attenuate the expression of tissue factor and selectins, to downregulate thrombin generation via the protein C pathway, and to directly and indirectly blunt platelet activation. Thus, in addition to its cholesterol-transporting properties, HDL favorably regulates endothelial cell phenotype and reduces the risk of thrombosis. With further investigation and resulting greater depth of understanding, these mechanisms may be harnessed to provide new prophylactic and therapeutic strategies to combat atherosclerosis and thrombotic disorders.
Key Words: atherosclerosis • endothelial nitric oxide synthase • endothelium • HDL • nitric oxide • prostacyclin • protein C • thrombin • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  J. Chen, X. Cui, A. Zacharek, C. Roberts, and M. Chopp eNOS Mediates TO90317 Treatment-Induced Angiogenesis and Functional Outcome After Stroke in Mice Stroke, July 1, 2009; 40(7): 2532 - 2538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rohrer, P. M. Ohnsorg, M. Lehner, F. Landolt, F. Rinninger, and A. von Eckardstein High-Density Lipoprotein Transport Through Aortic Endothelial Cells Involves Scavenger Receptor BI and ATP-Binding Cassette Transporter G1 Circ. Res., May 22, 2009; 104(10): 1142 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Anselmino, K. Malmberg, L. Ryden, and J. Ohrvik A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease Diabetes and Vascular Disease Research, April 1, 2009; 6(2): 62 - 70. [Abstract] [PDF]
|
|
|
|
 |
|
 K.-A. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter The metabolism and anti-atherogenic properties of HDL J. Lipid Res., April 1, 2009; 50(Supplement): S195 - S200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lu, M. E. T. Dolle, S. Imholz, R. van 't Slot, W. M. M. Verschuren, C. Wijmenga, E. J. M. Feskens, and J. M. A. Boer Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations J. Lipid Res., December 1, 2008; 49(12): 2582 - 2589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yao, E. S. Shao, M. Jumabay, A. Shahbazian, S. Ji, and K. I. Bostrom High-Density Lipoproteins Affect Endothelial BMP-Signaling by Modulating Expression of the Activin-Like Kinase Receptor 1 and 2 Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2266 - 2274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Rye and P. J. Barter Antiinflammatory Actions of HDL: A New Insight Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1890 - 1891. [Full Text] [PDF]
|
|
|
|
 |
|
 D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Postgrad. Med. J., November 1, 2008; 84(997): 590 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Hylek, L. Frison, L. E. Henault, and A. Cupples Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation: Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V Stroke, November 1, 2008; 39(11): 3009 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. de Albuquerque, C. E. Virgini-Magalhaes, F. Lencastre Sicuro, D. A. Bottino, and E. Bouskela Effects of Cilostazol and Pentoxifylline on Forearm Reactive Hyperemia Response, Lipid Profile, Oxidative Stress, and Inflammatory Markers in Patients With Intermittent Claudication Angiology, October 1, 2008; 59(5): 549 - 558. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Carnemolla, X. Ren, T. K. Biswas, S. C. Meredith, C. A. Reardon, J. Wang, and G. S. Getz The Specific Amino Acid Sequence between Helices 7 and 8 Influences the Binding Specificity of Human Apolipoprotein A-I for High Density Lipoprotein (HDL) Subclasses: A POTENTIAL FOR HDL PREFERENTIAL GENERATION J. Biol. Chem., June 6, 2008; 283(23): 15779 - 15788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart, June 1, 2008; 94(6): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor Eur. Heart J. Suppl., March 1, 2008; 10(suppl_B): B16 - B23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhu, S. Saddar, D. Seetharam, K. L. Chambliss, C. Longoria, D. L. Silver, I. S. Yuhanna, P. W. Shaul, and C. Mineo The Scavenger Receptor Class B Type I Adaptor Protein PDZK1 Maintains Endothelial Monolayer Integrity Circ. Res., February 29, 2008; 102(4): 480 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Valiyaveettil, N. Kar, M. Z. Ashraf, T. V. Byzova, M. Febbraio, and E. A. Podrez Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI Blood, February 15, 2008; 111(4): 1962 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomaraschi, L. Calabresi, G. Rossoni, S. Iametti, G. Franceschini, J. A. Stonik, and A. T. Remaley Anti-Inflammatory and Cardioprotective Activities of Synthetic High-Density Lipoprotein Containing Apolipoprotein A-I Mimetic Peptides J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Van Eck, M. Hoekstra, R. B. Hildebrand, Y. Yaong, D. Stengel, J. K. Kruijt, W. Sattler, U. J.F. Tietge, E. Ninio, T. J.C. Van Berkel, et al. Increased Oxidative Stress in Scavenger Receptor BI Knockout Mice With Dysfunctional HDL Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2413 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Affara, B. Dunmore, C. Savoie, S. Imoto, Y. Tamada, H. Araki, D. S. Charnock-Jones, S. Miyano, and C. Print Understanding endothelial cell apoptosis: what can the transcriptome, glycome and proteome reveal? Phil Trans R Soc B, August 29, 2007; 362(1484): 1469 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Parastatidis, L. Thomson, D. M. Fries, R. E. Moore, J. Tohyama, X. Fu, S. L. Hazen, H. F.G. Heijnen, M. K. Dennehy, D. C. Liebler, et al. Increased Protein Nitration Burden in the Atherosclerotic Lesions and Plasma of Apolipoprotein A-I Deficient Mice Circ. Res., August 17, 2007; 101(4): 368 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Gharavi, P. S. Gargalovic, I. Chang, J. A. Araujo, M. J. Clark, W. L. Szeto, A. D. Watson, A. J. Lusis, and J. A. Berliner High-Density Lipoprotein Modulates Oxidized Phospholipid Signaling in Human Endothelial Cells From Proinflammatory to Anti-inflammatory Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1346 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eichinger, N. M. Pecheniuk, G. Hron, H. Deguchi, M. Schemper, P. A. Kyrle, and J. H. Griffin High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism Circulation, March 27, 2007; 115(12): 1609 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Touyz Regulation of Endothelial Nitric Oxide Synthase by Thrombin Hypertension, March 1, 2007; 49(3): 429 - 431. [Full Text] [PDF]
|
|